Loading clinical trials...

SHR-1701 Combined with SHR2554 and BP102 for MCRC | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE2

SHR-1701 Combined with SHR2554 and BP102 for MCRC

An Explorative Study of SHR-1701 Combined with SHR2554 and BP102(bevacizumab) for Metastatic Colorectal Cancer.

NCT06679673•Fudan University

View on ClinicalTrials.gov

Summary

Response to oncologic treatment in mCRC is currently limited.

Detailed Description

This is a single-center, open-labeled study exploring the efficacy and safety of SHR-1701 combined with SHR2554 and BP102 in the treatment of metastatic colorectal cancer (mCRC) .

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18-75 years;
•Histological confirmed metastatic colorectal cancer;
•ECOG PS 0-1;
•At least one measurable lesion (according to RECIST1.1);
•Adequate hepatic, renal, coagulation, and hematologic functions;
•Agree to use contraception during the study and 3 months after the end of the study. Negative serum pregnancy test at screening for women of childbearing potential;
•Patients voluntarily enroll in the study.

Exclusion Criteria

•The patient has had other malignant tumors within 5 years (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
•Symptomatic brain or meningeal metastases (except for those whose BMS disease is stable for at least 4 weeks);
•Allergy to the study drug or any of its excipients;
•Prior treatment with immune checkpoint inhibitors;
•Received the following treatments before the first study treatment;
•1. Major surgery within 28 days before treatment (tissue biopsy for diagnostic purposes is permitted).
•2. Prior use of immunosuppressive medications, excluding nasal and inhaled corticosteroids or physiologic doses of systemic steroids (i.e., no more than 10 mg/d prednisone or equivalent pharmacologic doses of other corticosteroids) within 7 days before treatment;
•3. Received immunomodulatory drugs within 3 weeks before treatment;
•4. Received live attenuated vaccine within 28 days before treatment;
•5. Receipt of other antitumor systemic therapy within 28 days prior to treatment;
+14 more criteria

Locations (1)

Department of Colorectal Surgery Fudan University Shanghai Caner Center

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

December 1, 2024

Primary Completion Date

December 1, 2025

Completion Date

December 1, 2026

Last Updated

November 7, 2024

Enrollment

ESTIMATED participants

Conditions

Colorectal Cancer Metastatic

Interventions

SHR-1701

DRUG

BP102

DRUG

SHR2554

DRUG

Contacts

Ye Xu, Prof.

CONTACT

+86-21-6417-5590 xu_shirley021@163.com

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer

NCT05759728

Colorectal Cancer Metastatic

View study

RECRUITINGEARLY_PHASE1

COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer

NCT07328087

Colorectal Cancer MetastaticColorectal Cancer Stage III+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 7, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

SHR-1701 Combined with SHR2554 and BP102 for MCRC

Inclusion Criteria

Exclusion Criteria

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer

COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer

STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis